Pancreatic Cancer Research

ResearcherTokai UniversityNo recent work listed

Masashi Morimachi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-6729-4285; OpenAlex author ID A5023736363. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

  1. miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. Co-author DOI 10.1038/s41598-022-22950-2↗
  2. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2020-207002↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aya Kawanishi · 2 shared papers, 2021–2022 · strength 0.29
  2. Toshio Nakagohri · 2 shared papers, 2021–2022 · strength 0.29
  3. Tsubasa Saika · 2 shared papers, 2021–2022 · strength 0.29
  4. Kenichi Hirabayashi · 2 shared papers, 2021–2022 · strength 0.29
  5. Naoya Nakamura · 2 shared papers, 2021–2022 · strength 0.29
  6. Masaki Miyazawa · 1 shared paper, 2022 · strength 0.16
  7. Tatehiro Kagawa · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.